Impact of Highly Active Antiretroviral Therapy on paediatric Human Immunodeficiency Virus-associated left ventricular dysfunction within the Johannesburg teaching hospital complex

被引:2
|
作者
Pepeta, Lungile [1 ]
Cilliers, Antoinette M. [2 ]
机构
[1] Walter Sisulu Univ, Dept Paediat, Dora Nginza Hosp, ZA-6001 Port Elizabeth, South Africa
[2] Univ Witwatersrand, Chris Hani Baragwanath Acad Hosp, Div Paediat Cardiol, Johannesburg, South Africa
关键词
Myocardial function; nutritional status; immunological status; HIV-POSITIVE PATIENTS; MITOCHONDRIAL TOXICITY; DILATED CARDIOMYOPATHY; INFECTION; CHILDREN; HEART; COMPLICATIONS; DISEASE; CELLS;
D O I
10.1017/S1047951112000078
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To analyse the outcome of children with left ventricular dysfunction placed on Highly Active Antiretroviral Therapy. Method: This study is a retrospective review of records of Human Immunodeficiency Virus-positive children with left ventricular dysfunction. Demographic data were collected. Left ventricular fractional shortening, CD4 percentage, viral load, and nutritional status were compared before and during antiretroviral therapy. Results: We reviewed the records of 34 Human Immunodeficiency Virus-positive children with left ventricular dysfunction. In all, 18 patients received antiretroviral therapy (group one) and 16 were antiretroviral therapy naive (group two). The median age of group one at initial visit was 94 months, with a male-to-female ratio of 1:1. Of those, 17 children showed improved left ventricular function on treatment, with an increase in fractional shortening (median: 17-33.5%; p less than 0.0001). There was no significant statistical difference between the groups regarding initial fractional shortening. In group one, the CD4 percentage improved (median: 12% to 30.5%; p less than 0.0001), with viral load suppression (median: 24,900 copies per millilitre to less than 25 copies per millilitre; p less than 0.0001). There was weight gain in group one (median z-score: -1.70 to -1.32; p equal to 0.0083). Proper statistical analysis in group two was not possible because of poor follow-up of patients. Conclusion: The findings are in keeping with other reports that have shown improvement in left ventricular function in patients with Human Immunodeficiency Virus-associated cardiomyopathy treated with Highly Active Antiretroviral Therapy. Recovery of myocardial function is associated with improvement in immunological and nutritional statuses.
引用
收藏
页码:564 / 573
页数:10
相关论文
共 50 条
  • [1] The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy
    Sacktor, N
    JOURNAL OF NEUROVIROLOGY, 2002, 8 : 115 - 121
  • [2] Declining Incidence of Systolic Left Ventricular Dysfunction in Human Immunodeficiency Virus-Infected Individuals Treated With Highly. Active Antiretroviral Therapy
    Fisher, Stacy D.
    Starc, Thomas J.
    Guerra, Vitor
    Williams, Paige L.
    Wilkinson, James D.
    Lipshultz, Steven E.
    AMERICAN JOURNAL OF CARDIOLOGY, 2016, 117 (07): : 1194 - 1195
  • [3] Non-Hodgkin lymphomas after remission of human immunodeficiency virus-associated lymphomas in the highly active antiretroviral therapy era
    Luis Patier, Jose
    Angeles Moreno-Cobo, Maria
    Garcia-Cosio, Monica
    Montalban Sanz, Carlos
    MEDICINA CLINICA, 2013, 141 (09): : 411 - 412
  • [4] Human Immunodeficiency Virus-Associated Primary Lung Cancer in the Era of Highly Active Antiretroviral Therapy: A Multi-Institutional Collaboration
    D'Jaen, Gabriela A.
    Pantanowitz, Liron
    Bower, Mark
    Buskin, Susan
    Neil, Nancy
    Greco, Erin M.
    Cooley, Timothy P.
    Henry, David
    Stem, Jonathan
    Dezube, Bruce J.
    Stebbing, Justin
    Aboulafia, David M.
    CLINICAL LUNG CANCER, 2010, 11 (06) : 396 - 404
  • [5] Pharmacological impact of antiretroviral therapy on platelet function to investigate human immunodeficiency virus-associated cardiovascular risk
    Taylor, Kirk A.
    Smyth, Erica
    Rauzi, Rancesca
    Cerrone, Maddalena
    Khawaja, Akif A.
    Gazzard, Brian
    Nelson, Mark
    Boffito, Marta
    Emerson, Michael
    BRITISH JOURNAL OF PHARMACOLOGY, 2019, 176 (07) : 879 - 889
  • [6] Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era
    Cerrato, Enrico
    D'Ascenzo, Fabrizio
    Biondi-Zoccai, Giuseppe
    Calcagno, Andrea
    Frea, Simone
    Marra, Walter Grosso
    Castagno, Davide
    Omede, Pierluigi
    Quadri, Giorgio
    Sciuto, Filippo
    Presutti, Davide
    Frati, Giacomo
    Bonora, Stefano
    Moretti, Claudio
    Gaita, Fiorenzo
    EUROPEAN HEART JOURNAL, 2013, 34 (19) : 1432 - +
  • [7] Progressive human immunodeficiency virus-associated vasculopathy: time to revise antiretroviral therapy guidelines?
    Ntusi, N. B. A.
    Taylor, D.
    Naidoo, N. G.
    Mendelson, M.
    CARDIOVASCULAR JOURNAL OF AFRICA, 2011, 22 (04) : 197 - 200
  • [8] Effect of highly active antiretroviral therapy on cardiovascular involvement in children with human immunodeficiency virus infection
    Plebani, A
    Esposito, S
    Pinzani, R
    Fesslova, V
    Bojanin, J
    Salice, P
    Rossi, M
    Principi, N
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2004, 23 (06) : 559 - 563
  • [9] Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children
    Granados, JMS
    Amador, JTR
    De Miguel, SF
    Tomé, MIG
    Conejo, PR
    Vivas, PF
    Pollán, JC
    Contreras, JR
    Espert, AN
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2003, 22 (10) : 863 - 867
  • [10] Lupus anticoagulant in human immunodeficiency virus -infected patients on highly active antiretroviral therapy
    Awodu, Omolade A.
    Olayemi, Edeghonghon E.
    Bazuaye, Godwin N.
    Onunu, Abel N.
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2010, 53 (01) : 47 - 49